Shares of Aryx Therapeutics, the Fremont biopharmaceutical, got bombed Wednesday following news released late the day before that its latest clinical trial of tecafarin, its novel blood-clot treatment, failed to achieve better results than wafarin, a blood-thinner sold by Bristol- Myers Squibb that was developed six decades ago.
Ayrx’s stock ended the trading day falling Read the rest of this entry »
Xenoport, the Santa Clara biopharmaceutical, reported positive preliminary results today from a Phase 2 clinical trial of its treatment for patients with spasticity related to spinal cord injury. Patients given twice-daily doses showed “statistically significant improvement” compared to those receiving a placebo.
The company also said the drug candidate, arbaclofen placarbil, was Read the rest of this entry »
Shares of Xenoport hit a 52-week low Monday, diving $2.62, or 15 percent, to close at $14.76 after the Santa Clara drug maker and its partner, GlaxoSmithKline, reported that a clinical trial of its treatment for neuropathic pain associated with diabetic peripheral neuropathy in adults “did not demonstrate a statistically significant improvement” when compared to a placebo.
In November, Xenoport’s shares got similarly slammed when Read the rest of this entry »
Affymax, the Palo Alto biopharmaceutical, saw its shares rise $2.71, or 22 percent, to $14.91 in regular trading Thursday after Credit Suisse and its affiliates disclosed holding a 13.9 percent stake in the company, for which it paid $10 million.
After the closing bell, the company reported a net loss Read the rest of this entry »
CV Therapeutics, the Palo Alto biopharmaceutical company fending off unsolicited overtures from Japan’s second largest drug company, reported today that its new oral compound CVT-3619, designed to treat cardiometabolic diseases, was “well tolerated “with no serious adverse events and was associated with a reduction of free fatty acids.”
The Phase 1, single-blind, placebo-controlled, single-ascending-dose study involved 55 healthy and 23 obese volunteers. “No clinically meaningful changes in Read the rest of this entry »
Map Pharmaceuticals, the Mountain View development stage pharmaceutical company, said today that the initial Phase 3 clinical trial for budesonide for the potential treatment of children with asthma did not meet expectations in either of the doses evaluated when compared with a placebo.
The study included Read the rest of this entry »
Alexza Pharmaceuticals announced positive results from its second Phase 3 clinical trial of its inhalation drug candidate, AZ-004, otherwise known as Staccato loxapine, being developed to treat acute agitation in patients with schizophrenia or bipolar disorder. The drug’s development is part of a partnership between Mountain View-based Alexza and Symphony Capital, a biotech-focused private equity firm.
Alexza reported that the trials showed that both the 5 mg and 10 mg doses showed Read the rest of this entry »
CV Therapeutics said Thursday that European officials gave it the OK to market ranolazine, its treatment for patients suffering from angina, in all 27 states of the European Union. The move comes months after the European Medicines Agency gave a positive opinion Read the rest of this entry »
Aryx says its drug candidate ATI-7505 designed to treat chronic constipation and abdominal pain passed “an important cardiac safety study” conducted under a collaboration agreement with Procter & Gamble Pharmaceuticals, according to one of the press releases the company put out Wednesday.
Unfortunately for Aryx, a second release it put out disclosed that P&G has chosen to use a “one-time thirty day cancellation option” to withdraw from that same agreement. Read the rest of this entry »
Aryx Therapeutics “regretfully announced” Monday that it wouldn’t be able to make a presentation as previously planned at a healthcare conference Wednesday put together by New York investment firm Jeffries.
Aryx said it is working with its partner, the pharmaceutical arm of Procter & Gamble, Read the rest of this entry »
Subscribe via RSS all feeds